Cancer vaccine CEA-TRICOM - sanofi pasteur/Therion Biologics

Drug Profile

Cancer vaccine CEA-TRICOM - sanofi pasteur/Therion Biologics

Alternative Names: CEA-TRICOM

Latest Information Update: 08 Mar 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA); Therion Biologics
  • Developer Georgetown University; National Cancer Institute (USA); Therion Biologics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 08 Mar 2005 Discontinued - Phase-I for Colorectal cancer in USA (unspecified route)
  • 08 Mar 2005 Discontinued - Phase-I for Pancreatic cancer in USA (unspecified route)
  • 19 Jan 2005 Aventis Pasteur is now called sanofi pasteur
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top